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Objectives: A new technique, transmyocardial laser revascu!arization, pro- 
vides direct perfusion of ischemic myocardium via laser-created transmu- 
ral channels. From 1993 to 1995, we have treated 20 patients (mean age 61 
years, four women and 16 men) with transmyocardial laser revasculariza- 
tion. Preoperatively, the average angina class was 3.7. The patients were 
screened before the operation by a technetium sestamibi perfusion scan to 
identify the location and extent of their reversible ischemia. Methods: 
Operative exposure is gained via a left anterior thoracotomy. With the use 
of a 850-watt carbon dioxide laser, an average of 21 +- 4 channels were 
created in 22 minutes with a total operative time of less than 2 hours. 
Results: The in-hospital mortalily was two of 20 patients. Three additional 
patients died after discharge. Mter an accumulated 172 patient-months 
(mean followlup 11 - 8 months, range 1 to 26 months), the mean angina 
class is I (p = 0.01). Postoperative sestamibi scans were obtained at 3, 6, 
and 12 months. Using the septum as a control and comparing the 
postoperative results with the preoperative baseline, we noted a significant 
improvement in perfusion particularly in the areas of reversible ischemia. 
Conclusion: These early results indicate that transmyocardial laser revascu- 
larization is a simple operative technique that may improve myocardial perfusion 
an d provide angina relief for patients in whom standard methods of revascu- 
larization is contraindicated. (J Thorac Cardiovasc Surg 1996;111:!047-53) 
T he purpose in treating ischemic heart disease is the improvement ofblood flow to underperfnsed 
myocardium. The mainstays of this treatment are 
coronary artery bypass grafting (CABG) and percu- 
taneous transluminal coronary angioplasty (PTCA). 
Even with the success of these interventions, many 
patients with disabling angina re not candidates for 
these procedures because of diffuse end-stage coro- 
nary vascular disease, Indirect methods of myocar- 
dial revascularization have been tried, such as 
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Beck's poudrage and omentopexy, 1 Vineberg's tho- 
racic artery implantation, 2 and Sen's myocardial 
acupuncture. 3'4 These techniques provided some 
benefit but were eventually replaced by CABG and 
PTCA. The basis of these early methods i neovascu- 
larization of the ischemic myocardium. Mirohseini and 
associates s9 proposed the use of a laser to create 
transmyocardial channels tO provide direct perfusion 
of the myocardium with ventricular blood: They com- 
bined this transmyocardial laser evascularization with 
CABG and achieved promising results. 
After initial experimental work in our laboratory, 
which demonstrated improved regional contractility 
and patent channels 30 days after laser treatment of
an acute infarct, 1°' 11 we began a clinical study of 
transmyocardial l ser revascularization. We report 
the initial clinical results of using laser revascular- 
ization as sole therapy for patients with severe 
angina untreatable by conventional methods. 
Patients and methods 
Between March 1993 and April 1995, 20 patients were 
treated with transmyocardia! laser evascularization at the 
Brigham and Women's Hospital, Boston. The inclusion 
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Fig. 1. A, Preoperative Canadian Angina Class in 20 patients. B, Postoperative Canadian Angina Class in 
11 patients with at least 3 months' follow-up. 
Table I. Angina class, admissions, and nitroglycerin use 
Postoperative Postoperative 
(3-12 too) (13-26 too) 
Preoperative 
(n = 16") n = 11 p? n = 8 p~ 
Angina class 3.7 ± 0.5 1 ± 0.9 0.01 1 ± 0.9 0.01 
Admissions 28~ 4 0.001 4 
TNG/week 8 ± 4 1 ± 1 0.001 1 ± 0.8 0.001 
All values are expressed as the mean + standard eviation. TNG, Sublingual nitroglycerin. 
*Excludes the four deaths which have no follow-up. 
tp versus preoperative value. 
~:Number Of admissions for angina in the 12 months before transmyocardial l ser revascularization. 
criteria for acceptance into this study were threefold: (1) 
The patients had severe angina refractory to maximal 
medical therapy; (2) they had reversib!e myocardial isch- 
emia as documented by a technetium 99m (99mTc) sesta- 
mibi perfusion scan; (3) they were r/ot candidates for 
PTCA, CABG, or heart ransplantation. 12 The reasons for 
the inability to undergo PTCA or CABG included severe 
diffuse disease, inadequate distal targets, and lack of a 
conduit. If the patient had depressed ventricular function 
and was a candidate for transplantation, he or she was not 
enrolled for transmyocardial l ser revascularization. 
The study was approved by the institutional review 
board at the Brigham and Women's Hospital. Informed 
consent was obtained from each patient enrolled. 
Of the 20 patients, four (25%) were women. The 
average age was 61 _+ 10 years (mean _+ standard evia- 
tion) with an age range of 47 to 79 years. Ten of the 
patients (50%) had diabetes. The average cholesterol 
level on admission was 233 mg/dl. On average, the pa- 
tients had had one previous myocardial infarction. All had 
severe three-vessel coronary artery disease and all had 
already" undergone previous revascularization procedures. 
Eighteen (90%) had had at least one previous CABG and 
six (30%) of these had already had a second CABG. An 
average of five vessels had been bypassed with a range of 
two to ten grafts per patient. PTCA was done in two 
(10%) of the patients. Their average left ventricular 
ejection fraction was 45% _+ 10% (range 25% to 70%). 
The distribution of patients according to preoperative 
angina class is depicted in Fig. 1,A. The average Canadian 
Angina Class and number of hospital admissions for 
angina in the year before transmyocardial l ser revascu- 
larization are listed in Table I. 
All of the patients were receiving multiple medications 
to control their angina. Preoperatively, seven (35%) were 
being treated with intravenous heparin and five of these 
patients were also receiving intravenous nitroglycerin. 
Nineteen (95%) were receiving/3-blockers, 17 (85%) were 
receiving calcium channel blockers, and 16 (80%) were 
being treated with long-acting nitrates. All of the patients 
were taking sublingual nitroglycerin for exacerbations of
their angina, averaging approximately six to eight tablets 
per week. 
All of the patients underwent rest and stress 99~Tc 
sestamibi scanning before the operation to assess the 
extent and reversibility of their myocardial ischemia. 
When able, the patients were stressed by exercise; other- 
wise, they received ipyridamole (Persantine) at a rate of 
0.56 mg/kg per minute over 4 minutes by intravenous 
infusion. 
Operative technique. The status of all patients was 
monitored uring and after the operation with an arterial 
line and a pulmonary artery catheter. A thoracic epidural 
block was placed when possible to provide postoperative 
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pain relief. The patients were intubated with a double- 
lumen endotracheal tube, and a transesophageal chocar- 
diography (TEE) probe was inserted. A baseline TEE 
study was performed to evaluate the global ventricular 
function, as well as to determine areas of regional wall 
motion abnormalities and valvular disease. The patients 
were positioned in a 45-degree lateral decubitus position 
and underwent a left anterolateral thoracotomy through 
the fifth or sixth intercostal space depending on the 
location of the point of maximal impulse. The pericardium 
was entered anterior to the phrenic nerve and the heart 
was suspended in a pericardial cradle. Care was taken to 
avoid the previous CABGs. As determined by the pa- 
tient's preoperative 99mTc sestamibi scan, the area of 
reversible ischemia was exposed. It was this area that was 
then treated with the laser. 
Laser technology. The laser was a 1000-watt carbon 
dioxide device that delivered 850 watts of peak power to 
the tissue. The maximum output was 80 joules and the 
pulse width .could be varied from 1 to 99 msec. The 
operative settings were a pulse energy of 36 joules and a 
pulse width of 45 msec. The carbon dioxide laser was 
aimed with helium-neon laser guidance, placed against 
the epicardium, and fired. The laser was triggered to fire 
on the r wave of the electrocardiographic cy le when the 
ventricle was maximally distended and electrically quies- 
cent. The laser energy was absorbed by the blood in the 
ventricle, and this produced an acoustic image analogous 
to steam, which was readily visible by TEE in the long-axis 
four-chamber view. This vaporized tissue and blood de- 
noted transmyocardial penetration. Only shots verified by 
TEE were considered to have traversed the myocardium. 
The channels were 1 mm in diameter and were arrayed in 
a distribution of one per square centimeter. Bleeding from 
the channels was controlled with direct finger pressure or 
an epicardial suture if the pressure was not adequate. 
Epicardial suturing was required for less than 1% of the 
holes drilled. 
Follow-up. The patients returned 3, 6, 12, and 24 
months after the operation for repeated 99mTc sestamibi 
scans. The follow-up scans for each patient were con- 
ducted in the same fashion as the preoperative study. The 
scans were analyzed and scored by two observers in a 
blinded fashion. The nuclear medicine results were based 
on counting the number of segments with fixed ischemia 
and the number of segments with reversible ischemia as 
viewed on the short-axis cans of the left ventricle. The 
follow-up studies were compared with the preoperative 
baseline scans and the change in the number of involved 
segments was calculated. A difference of two segments or 
more was considered significant. The septum was not 
treated by transmyocardial l ser revascularization in any 
of the cases and thereby served as a control to which the 
treated left ventricular free wall was compared. 
The patients were examined at the aforementioned 
intervals, and they answered a standardized questionnaire 
designed to assess angina class, activity level, medications, 
and hospitalizations since the procedure. An unpaired 
Student's t test was used to compare the results. Differ- 
ences were considered significant at p < 0.05. Unless 
otherwise indicated, results are expressed as mean -+ 
standard eviation. 
Table II. Operative statistics 
Channels 21 -4- 4 
Energy (joule) 36 
Pulse width (msec) 45 
Operative time (min) 118 _+ 18 
Lasering time (min) 22 _+ 6 
EBL (ml) 150 _+ 50 
All values expressed as mean _+ standard eviation. EBL, Estimated blood 
loss, 
Results 
The operative statistics are listed in Table II. The 
morbidity of the procedure was minimal. No reop- 
erations for bleeding, wound infections, pneumo- 
thoraces, or transfusions were required. No laser- 
induced arrhythmias developed, and only one 
patient had postoperative atrial fibrillation. Ten of 
the patients were extubated in the operating room 
and the remainder were extubated in the first 36 to 
48 hours after the operation. The average stay in the 
intensive care unit was 2 _+ 1 days. The average 
hospital stay was 8 _+ 3 days. The patients were 
restarted on their preoperative medications, an(] 
these were adjusted as needed in the postoperative 
period. 
Four deaths (20%) occurred within 30 days of the 
procedure. Two patients died in the first 48 hours 
after the operation, one of a septal infarction that 
was evolving at the time of the operation (as deter- 
mined by infarct age at autopsy) and the other of an 
epidural overdose. Two patients died after dis- 
charge. One died on postoperative day 12 (2 days 
after discharge) of a presumed arrhythmia (autopsy 
revealed no other obvious cause of death). The 
other died on postoperative day 18 (11 days after 
discharge) of bleeding in the upper gastrointestinal 
tract and pneumonia (as confirmed by autopsy). The 
lone late death occurred in a patient who died 6 
months after the operation in a house fire. 
The remaining 15 patients have been followed up 
for 11 _+ 8 months (range 1 to 26 months) with an 
accumulated 172 patient-months of follow-up. The 
average Canadian Angina Class, angina-related hos- 
pital admissions, and nitroglycerin use are listed in 
Table I. These results are divided into early results 
(3 to 12 months postoperatively) and late results (12 
to 26 months postoperatively). The distribution of 
patients according to postoperative angina class is 
depicted in Fig. 1, B. 
No patient has required increased dosages or 
types of medications from preoperative levels or 
regimens. 
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Fig. 2. A, 99mTc sestamibi scan results of the septum. The septum was untreated by the laser and thereby 
served as a control. There is no evidence for improved perfusion in either the fixed or reversible segments 
with time. Fixed, Fixed segments (decreased perfusion at rest and stress); Rev, reversible segments 
(decreased with stress);p value versus preoperative baseline scan. B, 99mTc sestamibi scan results of the left 
ventricular f ee wall. The laser-treated left ventricular f ee wall shows improved perfusion in both the fixed 
and reversible segments with time. Fixed, Fixed segments (decreased perfusion at rest and stress); Rev, 
reversible segments (decreased with stress); p value versus preoperative baseline scan. 
The myocardial perfusion scan results are de- 
picted in Fig. 2, A and B. In Fig. 2, A, the changes in 
both fixed and reversible areas of ischemia in the 
septum are charted. Over time there was no signif- 
icant change in the number of septal segments with 
either fixed or reversible abnormalities. Inasmuch as 
the septum was not treated by the laser, these areas 
serve as a control and are contrasted with the 
changes een in the laser-treated left ventricular f ee 
wall (Fig. 2, B). There is a significant improvement 
in the areas of reversible ischemia with time when 
compared with the preoperative baseline scans. This 
improvement approaches ignificance in the fixed 
segments as well, but at best it attains a p value of 
0.05 at the 6-month interval. All of the treated areas, 
both the fixed and reversible segments, showed 
improved perfusion when compared with the sep- 
tum. 
Discussion 
A review of comparative anatomy demonstrates 
that myocardial perfusion in reptiles is primarily via 
blood from the ventricle through transmural chan- 
nels. Hence the reference to Sen's operation as the 
"snake heart" procedure. 3' 4 Wearn and associates 13
described similar channels in the human heart that 
allowed direct perfusion of the myoeardium. At- 
tempts to mechanically create these channels with 
the use of needles, tubes, and tunnels yielded vary- 
ing results. 14-19 Mirohseini and associates s'6 pio- 
neered the use of a laser to replicate the reptilian 
anatomy in a series of patients in the early 1980s. 
They achieved symptomatic relief and improved 
perfusion with a lower-power carbon dioxide laser 
used in conjunction with CABG. Because these 
patients underwent a combined laser/CABG proce- 
dure, evaluation of the results and the contribution 
of transmyocardial l ser revascularization to these 
results is difficult. 
In an effort to investigate the efficacy of transmyo- 
cardial laser revascularization, we initially per- 
formed a series of experiments in a large animal 
model of acute myocardial infarction. I°' 1i The re- 
sults from these experiments indicated that the 
procedure provided recovery of contractility in the 
infarct area at 3 hours and at 30 days. Histologic 
study of the channels at these times demonstrated 
evidence of patency, minimal thermal damage, and 
viability of the surrounding myocardium. Using 
these experimental data as scientific background, we 
began a clinical study of transmyocardial l ser re- 
vascularization as sole therapy for severe angina. 
Subjectively, the patients' symptoms improved 
immediately after the procedure and continued to 
improve during the follow-up period. Related to 
these findings is the decreased medication use, 
including diminished nitroglycerin i take. Although 
the placebo effect may influence the results of 
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transmyocardial laser revascularization early on, this 
effect is unlikely to last for 1 or 2 years. 
Objectively, the patients have shown improved 
perfusion in the treated areas. These improvements 
are most apparent between 3 and 6 months and have 
persisted after 1 and 2 years. The patients' septal 
scan results, shown in Fig. 2, A, did not significantly 
improve with time, but the laser-treated left ventric- 
ular free wall did show increased perfusion with 
time (Fig. 2, B). Similar results have also been 
observed by Frazier and associates 2° at the 3- and 
6-month intervals. In addition to symptomatic im- 
provement, the group at the Texas Heart Institute 
has demonstrated improved perfusion with positron 
emission tomographic scanning. 2° 
The exact mechanism by which transmyocardial 
laser revascularization may improve perfusion and 
thereby provide angina relief is unknown. Theoret- 
ically, the channels provide a passage for blood to 
flow from the ventricle into the myocardium, where 
it may diffuse into the interstitium or be further 
transported by blood vessels intersecting the chan- 
nels. A pressure gradient across the myocardium 
would encourage this flow. 8'21-23 With time, the 
channels may become endothelialized. 8 The pres- 
ence of these channels and the energy delivered by 
the laser to the myocardium may stimulate angio- 
genesis, which would further improve perfusion via 
collateral formation. If so, angiogenesis may be 
supplemented by seeding the channels with angio- 
genic growth factors. 24'25 Further experimental 
work is planned to investigate the mechanism of 
transmyocardial laser revascularization. 
Clinically, transmyocardial laser revascularization 
may also be useful in treating transplant recipients, 
whose diffuse atherosclerosis i  due to chronic re- 
jection, 26-2s which makes standard grafting untena- 
ble. The largest use for transmyocardial laser revas- 
cularization will be in conjunction with CABG for 
patients in whom standard bypass grafting cannot be 
adequately accomplished in all territories because of 
the lack of distal targets or the lack of a conduit. 
First, however, we are planning to begin a random- 
ized controlled trial of transmyocardial laser revas- 
cularization alone to be compared with medical 
therapy for angina. 
In conclusion, our results at 2 years indicate that 
use of transmyocardial laser revascularization may 
relieve angina, improve perfusion, and decrease 
hospital admissions in a cohort of patients who are 
otherwise untreatable by conventional revascular- 
ization. 
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Discussion 
Drl Reinold Jones (San Francisco, Calif.). Dr. Horvath 
and his associates have accurately portrayed the laser 
technology, patient selection, and surgical techniques in 
the performance of transmyocardial l ser revasculariza- 
tion. Their group is to be complimented ontheir excellent 
results. 
Phase I of the Food and Drug Administration (FDA) 
clinical trial was started in January 1990 with Dr. John 
Crew as the principal investigator. In phase I we were 
permitted 15 patients. The first patient is still alive at 87 
years of age with no angina. 
In our early experience the only assurance of a patent 
laser channel into the left ventricle was by subjective 
observation ofa spurt of blood after the laser strike. In the 
sixth case, we implemented the use of TEE, which visu- 
alizes a jet of bubbles when the laser energy strikes blood 
in the left ventricle. Only positive shots by TEE are 
considered as completed channels. These bubbles are not 
steam but elemental gases produced by photomolecular 
disruption from carbon dioxide laser energy. Using trans- 
cranial Doppler ultrasonography, we hear the bubbles 
reaching the middle cerebral artery in small amounts 
without neruologic sequelae. 
At the San Francisco Heart Institute Dr. Crew and I 
have now operated on 28 patients with no operative 
mortality. We have had three late deaths; one patient died 
3 months after the operation, angina-free, of a preexisting 
arrhythmia, one died 9 months after the operation of 
pulmonary disease, and one died at 29 months of a 
suspected myocardial infarction. 
In our series, Dr. Crew and I operated on only one 
patient who had no previous urgery, and she had vessels 
too small to bypass. Thirty-two months after the operation 
she has limited angina but is still working full time. 
We are now using our third prototype laser with 
modifications suggested by our initial experience in the 
phase I study of 15 patients. Nine centers are currently 
performing this procedure under FDA control and guide- 
lines. 
We wish to acknowledge the research and clinical work 
of Dr. Mirhoseini and his unfailing faith in this controver- 
sial procedure. 
The animal studies of Drs. Horvath and Cohn have 
demonstrated the validity of our clinical impressions. Drs. 
Cooley and Frazier have added further proof of revascu- 
larization with preoperative and postoperative positron 
emission tomographic s ans demonstrating increased me- 
tabolism invisible on initial thallium studies. 
I would like to ask a few questions: First, why does the 
thallium take so long to respond (3 to 6 months) when 
clinical success is so rapid? 
Dr. Horvath. That is a good question. When we de- 
signed this study we thought hat it was going be difficult 
to identify when to start using scans to remeasure perfu- 
sion. We were more interested in the long-term follow-up 
than in the immediate ffects. Therefore, we picked 3 
months arbitrarily as the first postoperative isit. We did, 
out of curiosity, obtain a few scans on some of the patients 
before their discharge and saw some improvement. That 
improvement seems to continue into the 6-month period, 
probably related to the fact that the laser channels tap into 
already existing collaterals and allow those collaterals to 
further develop. Some have even speculated that the laser 
energy itself allows for angiogenesis to occur and that is 
why perfusion continues to improve. 
Dr. Jones. Do you foresee the use of transmyocardial 
revascularization in patients with acute ischemia? 
Dr. Horvath. Our laboratory work was done in an acute 
ischemia model and we saw some striking results with 
that. The laser was able to salvage sheep that had acute 
infarcts. There may be an application for that, but as it 
stands the best use is going to be in the setting of chronic 
ischemia, again with an ability to tap into the already 
existing collaterals. 
Dr. Jones. Do you foresee the use of transmyocardial 
revascularization in high-risk patients uch as Jehovah's 
Witnesses? Dr. Crew attempted four video-assisted tho- 
racoscopic transmyocardial revascularizations i  Saudi 
Arabia with Dr. Raffa in November of 1994 on patients 
with no prior surgery. If transmyocardial revascularization 
is successfully proven to be valid and lasting, do you think 
this may be an initial viable alternative? 
Dr. Horvath. First we have to decide whether it is an 
alternative tobypass. However, in patients who have those 
types of restrictions, I think it is safe as far as blood loss is 
concerned and in fact may be a better alternative. 
Dr. D. Craig Miller (Stanford, Calif.). It has been 
controversial whether the microchannels actually remain 
open on the endocardial surface. Can you elaborate on 
your autopsy data? 
Dr. Horvath. We have seen on autopsy that the chan- 
nels are open. The channels appear to close near the 
epicardial surface approximately 100 to 300 txm from the 
surface on cross section. The most difficult part is to 
identify all of the channels at autopsy, especially with time 
and the natural healing process. It is very difficult to say 
that something is a channel versus a preexisting vessel, 
and that has been the limitation. 
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Dr. Ed Verrier (Seattle, Wash.). This same presentation 
was informally done by Larry Cohn before the Cardiac 
Surgery Biology Club a few months ago. It generated 
significant discussion and also engendered a review of the 
physiologic literature. It is safe to say that no physiologic 
study has shown either that the channels tay open or that 
there is subendocardial flow through the chamber into the 
functioning subendocardial muscle. You have presented 
clinical data that there may be a beneficial effect of using 
this procedure in the ischemic patient. There is also clear 
evidence that the condition of many patients with chronic 
angina will improve with medical therapy without his type 
of intervention. I believe that the controversy remains 
about justification for this expensive quipment without 
physiologic justification to benefit only a few patients. We 
need more information about how this works, particularly 
physiologic experimental information, because otherwise 
it resembles a Vineberg-type approach. 
Dr. Horvath. Transmyocardial laser revascularization 
has been called a "high-tech Vineberg." However, you 
have to remember that the Vineberg operation worked, 
and we have angiographic and metabolic data that show 
that there was perfusion via those types of grafts. I also 
agree that a large amount of work needs to be done to 
ascertain the mechanism--whether there is a short-term 
benefit from the channel itself carrying blood flow or 
Whether there is a more long-term benefit that results 
merely from delivering laser energy to the heart. The 
analogy that I have seen historically is the paper on 
ligation of the internal thoracic artery by Diamond's 
group in the early 1960s. They show that the patients 
subjectively improved as a result of ligation of the thoracic 
artery; however, that improvement did not continue be- 
yond 7 months. We have results that show subjective 
improvement at the 2-year interval, and we also have 
some objective proof of improved perfusion based on the 
nuclear medicine scans. There appears to be something 
working other than just "smoke and mirrors." 
Dr. John Benfield (Sacramento, Calif.). The history of 
myocardial revascularization is fascinating. It goes back at 
least o Claude Beck at the Cleveland Clinic putting talc in 
the pericardium to improve myocardial revascularization. 
Then there were the Glover procedure (internal thoracic 
artery ligation) and the Vineberg procedure (internal 
thoracic artery implantation). Now we have this proce- 
dure. Fortunately, scientific evaluation is underway. Be- 
fore this procedure becomes widely used, however, I wish 
to hear from you where and how and by whom and under 
what circumstances this procedure should be further 
tested. Presumably you do have institutional review board 
permissiqn to do this. What needs to happen ow to keep 
this procedure from being used prematurely in centers 
where it perhaps hould not be tried? 
Dr. ttorvath. First we need to perform more experi- 
mental work to develop the mechanism. On the clinical 
front, using it as sole therapy in patients for whom no 
other treatment is available is acceptable. That probably 
needs to continue and the follow-up needs to be contin- 
ued as well. At this point combining transmyocardial 
revascularization with bypass is dangerous because it is 
difficult to determine whether the benefit is due to the 
bypass or to the laser. The best study that we can do now 
is the new FDA protocol to compare transmyocardial 
laser revascularization with medical therapy after random- 
ization in patients with end-stage coronary vascular dis- 
ease. The results of this study will help to validate the 
procedure. 
Dr. Benfield. Perhaps my question was not entirely 
clear. Let's assume for a moment hat I'm a very active 
and highly thought of cardiac surgeon in a very good 
community hospital where my group and I might be doing 
600 successful bypass procedures a year. Should I consider 
undertaking this procedure as part of my practice? If so, 
why? If not, why not? If not, what step swould need to be 
taken before I should consider undertaking this procedure 
in my practice? 
Dr. Horvath. I think you should undertake it for 
patients for whom there are no other options. I do not 
think you should present it to patier/ts as an alternative to 
standard well-respected well-studied methods of revascu- 
larization such as bypass urgery. 
Dr. Miller. What are the FDA's prerequisites to enter 
the phase III trial? 
Dr. Itorvath. It has been hard to pin down what the 
FDA wants in the phase III trial. They want us to use the 
same criteria that we have used for entering patients into 
this sole therapy group. 
Dr. Miller. What institutions are going to be allowed to 
join your bandwagon? 
Dr. Itorvath. The FDA has limited the institutions to 
those currently included in the study, that is, the nine in 
the United States that are performing the procedure. 
Dr. George E. Miller (Pebble Beach, Calif.). In the 
mid-1960s, we and many other investigators attempted to 
show patency of transmyocardial channels connecting the 
left ventricle with the myocardial sinusoids in the experi- 
mental laboratory. These channels were produced by 
using large-bore cutting needles and extracting cores of 
myocardium from the left ventricle through to the epicar- 
dium, then closing the epicardium. We were never able to 
demonstrate the late presence of patent channels. Why 
would channels produced by laser remain open whereas 
those produced by steel scar over? 
Dr. Horvath. We have done that in the laboratory as 
well, as have other investigators. Using a needle, whether 
it be solid or cored, we have seen a great deal of tissue 
trauma that the body responds to by simply scarring over 
that area. There has not been any patency, either short or 
long term, when those types of techniques have been used. 
The laser completely eradicates the tissue. It does not 
simply push or tear it out of the way, as occurs with the 
more mechanical devices. I believe the channel stays open 
because of the laser's precise ability to ablate the tissue 
and allow the tissue to be eliminated. 
